3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Cholangiocarcinoma
2
Liver Neoplasms
1
Biliary Tract Neoplasms
1
Bile Duct Neoplasms
1
Interventions
Gemcitabine
45
Cisplatin
34
Oxaliplatin
23
Capecitabine
17
Fluorouracil
13
Leucovorin
12
pembrolizumab
11
lenvatinib
11
durvalumab
10
S 1 (combination)
10
Irinotecan
10
Bevacizumab
9
apatinib
7
Nivolumab
7
tremelimumab
6
Trastuzumab
5
envafolimab
4
atezolizumab
4
Injections
4
Docetaxel
4
trametinib
3
titanium silicide
3
tislelizumab
3
irinotecan sucrosofate
3
camrelizumab
3
Radiotherapy
3
Drug Therapy
3
zanidatamab
2
toripalimab
2
surufatinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Biliary Tract Neoplasms
×
derazantinib
×
Clear all
NCT03230318
2023-12-19
FIDES-01
Basilea Pharmaceutica
Phase 2
Completed
148 enrolled
15 charts